Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections

Veterinary Microbiology

Volumn 131, Issue 1-2, 2008, Pages 164-172

  Rubin, J ^a   Walker, R D ^b,c   Blickenstaff, K ^d   Bodeis Jones, S ^d   Zhao, S ^d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Anti infectives Research Consultants   (United States)

^c and Mass Communication   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Antimicrobial resistance; Canine; Class 1 integron; Fluoroquinolones; Pseudomonas aeruginosa; QRDR

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTIOFUR; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; DIFLOXACIN; ENROFLOXACIN; GATIFLOXACIN; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; MARBOFLOXACIN; ORBIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFAFURAZOLE; TETRACYCLINE; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DISEASE PREDISPOSITION; DOG; DRUG SENSITIVITY; EXPERIMENTAL STUDY; EXTERNAL OTITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA; PYODERMA; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DNA, BACTERIAL; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; INTEGRONS; MICROBIAL SENSITIVITY TESTS; OTITIS; POINT MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYODERMA;

ANIMALIA; CANIS FAMILIARIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 48849084928     PISSN: 03781135     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetmic.2008.02.018     Document Type: Article

References (29)

1. Akasaka T., Tanaka M., Yamaguchi A., and Sato K. Type II topoisomerase mutations in flouroquinolone-resistamt clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45 (2001) 2263-2268
2. Cole L.K., Luu D.H., Rajala-Schultz P.J., Meadows C., and Torres A.H. In vitro activity of an ear rinse containing tromethamine, EDTA, and benzyl alcohol on bacterial pathogens from dogs with otitis. Am. J. Vet. Res. 67 (2006) 1040-1044
3. CLSI, 2004. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals, informational supplement. CLSI/NCCLS document M31-S1. Clinical and Laboratory Standards Institute, Wayne, PA.
4. CLSI, 2006. Performance standards for antimicrobial susceptibility testing, sixteenth informational supplement. CLSI/NCCLS ducument M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Fonseca E.L., Vieira V.V., Cipriano R., and Vicente A.C.P. Class 1 integrons in Pseudomonas aeruginosa isolates from clinical settings in Amazon region, Brazil. FEMS Immunol. Med. Microbiol. 44 (2005) 303-309
6. Gales A.C., Jones R.N., Turnidge J., Rennie R., and Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 32 Suppl. 2 (2001) 146-155
7. Gatoria I.S., Saini N.S., Rai T.S., and Dwivdei P.N. Comparison of three techniques for the diagnosis of urinary tract infections in dogs with urolithiasis. J. Small Anim. Pract. 47 (2006) 727-732
8. Goldstein C., Lee M.D., Sanchez S., Hudson C., Phillips B., Register B., Grady M., Liebert C., Summers A.O., White D.G., and Maurer J.J. Incidence of class 1 and 2 integrases in clinical and commensal bacteria from livestock, companion animals, and exotics. Antimicrob. Agents Chemother. 45 (2001) 723-726
9. Gu B., Tong M., Zhao W., Liu G., Ning M., Pan S., and Zhao W. Prevalence and characterization of class 1 integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China. J. Clin. Microbiol. 45 (2007) 241-243
10. Hall R.M. Mobile gene cassettes and integrons: moving antibiotic resistance genes in Gram-negative bacteria. Ciba Found. Symp. 207 (1997) 192-202
11. Hall-Stoodley L., Costerton J.W., and Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2 (2004) 95-108
12. Hariharan H., Coles M., Poole D., Lund L., and Page R. Update on antimicrobial susceptibilities of bacterial isolates from canine and feline otitis externa. Can. Vet. J. 47 (2006) 253-255
13. Health Canada, 2007. Therapeutic Products Directorate: Drug Product Database (DPD). www.hc-sc.ga.ca/dhp-mps/prodpharma/databasdon/index_e.html (accessed February 21, 2007).
14. Hillier A., Alcorn J.R., Cole L.K., and Kowalski J.J. Pyoderma caused by Pseudomonas aeruginosa infection in dogs-20 cases. Vet. Dermatol. 17 (2006) 432-439
15. Hooper D.C. Mode of action of fluoroquinolones. Drugs 58 Suppl. 2 (1999) 6-10
16. Jalal S., Ciofu O., Hoiby N., Gotoh N., and Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44 (2000) 710-712
17. Li X. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int. J. Antimicrob. Agents 25 (2005) 453-463
18. Li X., Livermore D.M., and Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob. Agents Chemother. 28 (1994) 1732-1741
19. Linder J.A., Huang E.S., Steinman M.A., Gonzalas R., and Stafford R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am. J. Med. 118 (2005) 259-268
20. Martinez M., McDermott P., and Walker R. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet. J. 172 (2006) 10-28
21. Mouneimne H., Robert J., Jarlier V., and Cambau E. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43 (1999) 62-66
22. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264 (1994) 382-388
23. Paramythiotou E., Lucet J.C., Timsit J.F., Vanjak D., Paugam-Burtz C., Trouillet J.L., Belloc S., Kassis N., Karabinis A., and Andremont A. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38 (2004) 670-677
24. Pirnay J., De Vos D., Cochez C., Bilocq F., Pirson J., Struelens M., Duinslaeger L., Cornelis P., Zizi M., and Vanderkelen A. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J. Clin. Microbiol. 41 (2003) 1192-1202
25. Prescott J.F., Hanna W.J.B., Reid-Smith R., and Drost Kelli. Antimicrobial drug use and resistance in dogs. Can. Vet. J. 43 (2002) 107-116
26. Talukder K.A., Khajanchi B.K., Islam M.A., Islam Z., Dutta D.K., Rahman M., Watanabe H., Nair G.B., and Sack D.A. Fluoroquinolone resistance linked to both gyrA and parC mutations in the quinolone resistance-determining region of Shigella dysenteriae Type 1. Curr. Microbiol. 52 (2006) 108-111
27. Tejedor M.T., Martin J.L., Navia M., Freixes J., and Vila J. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Vet. Microbiol. 94 (2003) 295-301
28. van Duijkeren E., Box A.T.A., Schellen P., Houwers D.J., and Fluit A.C. Class 1 integrons in Enterobacteriaceae isolated from clinical infections of horses and dogs in the Netherlands. Microb. Drug Resist. 11 (2005) 383-386
29. Zhao S., Qaiyumi S., Freidman F., Singh R., Foley S.L., White D.G., McDermott P.F., Donkar T., Bolin C., Munro S., Baron E.J., and Walker R.D. Characterization of Salmonella enterica serotype Newport isolated from humans and food animals. J. Clin. Microbiol. 41 (2003) 5366-5371